【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議 CKD >stage3 之老年人長期使用。

高血壓 (ARB) 治療心衰竭 Heart failure; Hypertension; Myocardial infarction

Valsartan is an orally active, nonpeptide angiotensin II receptor antagonist (ARB), selective for the AT1 receptor. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor subtype in many tissues (eg, vascular smooth muscle, adrenal gland). Its action is independent of the pathways for angiotensin II synthesis . It has no agonist activity of AT1 and its affinity for the AT1 receptor is approximately 20,000 times greater than for the AT2 receptor .

Bioavailability: 25%
Metabolism: CYP2C9
Excretion: Renal, mainly as unchanged drug
Elimination Half Life: 6 hours

Concomitant aliskiren use in diabetic patients.
Hypersensitivity to valsartan or any component of the product

D (FDA)

Infant risk cannot be ruled out.(MDX)

Common:
Cardiovascular: Hypotension (5.5% to 6.9% )
Neurologic: Dizziness (2% to 17% ), Headache (greater than 1% )
Renal: Serum blood urea nitrogen raised (heart failure, 16.6% ), Serum creatinine raised (hypertension, 0.8%; heart failure, 3.9%; post-myocardial infarction, 4.2% )
Respiratory: Cough
Serious:
Renal: Acute renal failure
Other: Angioedema, Face, lips, throat

Heart failure:
1. Initial: 40 mg ORALLY twice daily
2. Maintenance: 80 to 160 mg ORALLY twice daily as tolerated; MAX 320 mg daily
Hypertension:
1. Initial: 80 to 160 mg ORALLY once daily
2. Maintenance: 80 to 320 mg ORALLY once daily
Myocardial infarction:
1. Initial: 20 mg ORALLY twice daily
2. May be increased within 7 days to 40 mg twice daily ; titrate to 160 mg twice a day as tolerated

Hypertension: (6 to 16 years old)
1. Initial 1.3 mg/kg once daily; MAX 40 mg/day
2. Maintenance: up to 2.7 mg/kg once daily; MAX 160 mg/day